SCHEMBL2972014

SCHEMBL2972014

CNC(=O)CC(NC(=O)O)C1CCN(Cc2cc(-c3ccc(Cl)cc3)no2)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 2/20 0.44
DRD4 P21917 2/20 0.44
DRD3 P35462 2/20 0.44
LMNA P02545 1/20 0.43
POLB P06746 1/20 0.43
F10 P00742 1/20 0.43
SMN1; SMN2 Q16637 3/20 0.42
HTT P42858 2/20 0.42
JAK2 O60674 1/20 0.42
ALDH1A1 P00352 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
USP30 Q70CQ3 2/20 0.42
HDAC3 O15379 1/20 0.41
HDAC4 P56524 1/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC7 Q8WUI4 1/20 0.41
HDAC2 Q92769 1/20 0.41
HDAC10 Q969S8 1/20 0.41
HDAC11 Q96DB2 1/20 0.41
HDAC8 Q9BY41 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2981404 0.93 LMNA (0.42) DRD2DRD4DRD3LMNAPOLB
SCHEMBL2976745 0.90 JAK2 (0.42) DRD2DRD4DRD3LMNAPOLB
SCHEMBL2970163 0.82 SIGMAR1 (0.49) POLBALDH1A1HDAC1HDAC8HDAC6
Hydrochloric Acid SCHEMBL2971258 0.81 SIGMAR1 (0.48) POLBHDAC1HDAC8HDAC6
SCHEMBL2965446 0.80 MAPT (0.42) DRD2DRD4DRD3POLBF10
SCHEMBL2981428 0.79 MAPT (0.43) DRD2DRD4DRD3POLBF10
SCHEMBL2967606 0.79 HDAC3 (0.39) LMNASMN1; SMN2HTTJAK2ALDH1A1
SCHEMBL2972019 0.77 DRD2 (0.44) DRD2DRD4DRD3LMNAPOLB
SCHEMBL3606179 0.77 USP30 (0.52) DRD2DRD4DRD3LMNAPOLB
SCHEMBL2982160 0.76 MCHR1 (0.49) POLBL3MBTL1HDAC1CHRM4KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7781590-B2 Piperidinylalkylcarbamate derivatives, methods for their preparation and the therapeutic use thereof as fatty acid amido hydrolase enzyme inhibitors SANOFI-AVENTIS (FR) 2010-08-24 US disclosed
US-20070021403-A1 PIPERIDINYLALKYLCARBAMATE DERIVATIVES, METHODS FOR THEIR PREPARATION AND THE THERAPEUTIC USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS SANOFI-AVENTIS (FR) 2007-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070021403-A1 PIPERIDINYLALKYLCARBAMATE DERIVATIVES, METHODS FOR THEIR PREPARATION AND THE THERAPEUTIC USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS FAAH, FAAH2, CNR2 DRD2 1610/4885DRD4 1900/4885DRD3 1410/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.